MYGN Message Board - Msg: 19254313

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MYGN

MYGN 6.295

-3.0%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: A.J. Mullen who wrote (23)	8/28/2003 3:11:50 PM
From: A.J. Mullen	of 29

There have been downgrades from CSFB and Bear Stearns based primarily on the reduced growth of Predictive Medicine in the Q4 '03. That might have been a result of the winding down of their direct-to-consumer advertising; ie previous quarters must have been boosted by that. The expense of the tests ($ 000s per test) and their nature (long-term risk assessment) probably means that the uptake will be more dependent on the economy than most medicine. Year on year the growth rate of 29% for predictive medicine still seems respectable. In the conference call they were asked how the Lab Corps deal was progressing, they answered they expected a slow ramp-up. They seemed excited about the potential Alzheimer's drug, but warned not to expect results anytime soon. Likewise, no great announcement likely imminent for the other compounds. This too, seems to have figured in the downgrades. On the otherhand NIH is running studies to incorporate predictive medicine into care. This seems important. It doesn't help to know what may kill you unless it makes you more vigilant and early intervention helps Better still if it suggests a prophylactive treatment such as Tamoxifen. Ashley

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next